Pharma: Pressure grows continuously

The expectations that companies deal with sustainability risks are increasing. The pressure is also growing in the pharmaceutical industry. At first glance, the highly regulated industry does not need to worry too much in the so-called ESG area. However, controversies are looming, especially when it comes to social criteria.

Under the German Supply Chain Duty of Care Act, companies must ensure that human rights and environmental standards are complied with throughout the supply chain. From 2023 it will apply to companies with at least 3,000 employees and from 2024 to companies with at least 1,000 employees in Germany. At the end of February 2022, the EU Commission now presented the long-awaited proposal for an EU Supply Chain Act that goes beyond the requirements of the German law. It is intended to promote sustainable and responsible corporate behavior in all global value chains.

Sign up now and continue reading immediately